Mikoderil cream 1% 15g tube

Description

Composition
Active substance:
1 g of cream contains: naftifine hydrochloride – 10.0 mg.
Excipients:
Sodium hydroxide – 1.2 mg benzyl alcohol – 10.0 mg Sorbitan Stearate – 19.0 mg, cetyl palmitate – 20.0 mg Polysorbate 60 – 61.0 mg, cetostearyl alcohol – 80.0 mg, isopropyl myristate – 80 0 mg purified water – up to 1000 mg.
Description:
White homogeneous cream with low specific smell.
Product form:
Cream for external use 1%.
15 g aluminum tubes.
The tube together with instructions for medical application is placed in a pile of cardboard.
Contraindications
Hypersensitivity to naftifine, benzyl alcohol or other components of the formulation; pregnancy and lactation (safety and efficacy in these patients has not been studied).
Precautions: children’s age (clinical application experience is limited).
Dosage
1 %
Indications
Fungal infection of smooth skin and skin folds (tinea corporis, tinea inquinalis); interdigital mycosis (tinea manum, tinea pedum); Nail fungal infections (onychomycosis); Skin candidiasis; chromophytosis; dermatomycosis (with or without itching it).
Interaction with other drugs
It has not been studied.
Overdose
No cases of overdose have been reported.
pharmachologic effect
Pharmacodynamics:
Naftifine – antifungal agent for external use, referring to the class of allylamine. The mechanism of action is associated with inhibition of squalene epoxidase 2.3, which reduces the formation of ergosterol, a component of fungal cell walls. Active against dermatophytes such as Trichophyton, and epidermofiton mikrosporum, molds (Aspergillus spp.), Yeast (Candida spp., Pityrosporum) and other fungi (e.g., Sporothrix schenckii). In against dermatophytes and Aspergillus acts fungicidally naftifine. With respect to the preparation of yeasts exhibits fungicidal or fungistatic activity depending on the microorganism strain. It possesses antibacterial activity against Gram-positive and Gram-negative microorganisms that can cause secondary bacterial infection. It has anti-inflammatory action, which contributes to the rapid disappearance of the symptoms of inflammation, especially pruritus.
Pharmacokinetics:
When applied topically penetrates well into different layers of the skin, creating a stable antifungal concentrations of its various layers. After application to the skin is exposed to systemic absorption less than 6% naftifine. Quantity sucked partially metabolized and excreted through the intestines and kidneys. The half-life is 2 – 3 days.
Pregnancy and breast-feeding
Use of the drug during pregnancy and lactation is not recommended (safety and efficacy in these patients has not been studied).
Conditions of supply of pharmacies
Without a prescription.
side effects
The reaction may occur at the application site: dry skin, skin redness and burning. Side effects are reversible and do not require discontinuation of treatment. If any of these instructions side effects are compounded, or observed any other side effects not mentioned in the instructions, you should immediately inform your doctor.
special instructions
Required treatment course.
Precautions for use: Mikoderil® drug is not intended for use in ophthalmology. Do not allow contact with the drug in the eye.
Use in pediatrics: Precautions should use the drug in children under 18 years of age (efficacy and safety has not been proven).
Effects on ability to drive and use other mechanisms:
Mikoderil® not adversely affect the ability to drive and perform other activities that require concentration and speed of psychomotor reactions.
Storage conditions
At a temperature of not higher than 25 C.
Keep out of the reach of children.
Dosing and Administration
Outwardly.
When skin lesions Mikoderil® applied 1 time a day to the affected skin surface and the adjacent portions, after thorough cleaning and drying (approximately 1 cm capturing a healthy area of ​​skin around the edges of the affected area).
The duration of therapy with dermatomycosis – 2-4 weeks (if necessary – up to 8 weeks) at candidiasis – 4 weeks.
With the defeat of Mikoderil® polish is applied 2 times a day to the affected nail. Before the first use of the drug was removed as much as possible the affected part of the nail clippers or nail file.
The duration of therapy for onychomycosis – up to 6 months.
To prevent relapse, treatment should continue for at least 2 weeks after the disappearance of clinical symptoms.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist